Predictive biomarkers for optimal treatment selection in RCC are lacking. Gene expression data from
IMmotion151 and Javelin Renal 101 clinical trials generated anti-angiogenic and immune signatures that
warrant further validation. We aimed to describe the genomic and gene expression profiles in a multi-institutional database of patients with ccRCC, and its association with other biomarkers of interest.